Fetal Stem Cells -- Another Case Study in Media Hype

This is a warning about investor trawling, media hype, and the realities attendant to regenerative medicine.

Whenever a stem cell company, particularly one dealing with controversial tissues such as embyronic and fetal, announces CURES! CURES! CURES! the media goes into full hype mode -- unless it is an adult stem cell company, in which case bona fide successes are often ignored.

Then, when the controversial trial crashes and burns, the story is reported mildly as a business story of falling...